CardioSource WorldNews December 2014 - Page 24

THE BE T Multimedia Highlights From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video Making Sense of Conflicting Data: Neurologic Events in SAVR and TAVR Philippe Genereux, MD: “What we know is that before the TAVR era, the data on stroke after surgical aortic valve replacement were very scant. Part of the reason was that the education was not really systematic and was mainly site report.” Sex Differences and Response to PCI in Acute Myocardial Infarction: OCTAVIA Study Giulio Guagliumi, MD: “I think [the sex differences] are an important topic because of the increasing number of women coming to the hospital searching for care with acute MI. All of the data we have are very focused on and mainly derive from [studies of] men. That is an issue because when you are running bigger studies and you don’t have enough [women] coming in, you can’t tell the differences.” Single Breath-hold Compressed Sensing Strategy: Pote ntial to Replace Standard Cardiac MR Juerg Schwitter, MD: “We were just looking at left ventricular function in this paper, and it showed that if the data are registered in space with respect to respiratory motion, we are more precise than with techniques that we have today.” Guagliumi G, et al. J Am Coll Cardiol Vincenti G, et al. J Am Coll Cardiol Img. Intv. 2014;7:958-68. 2014;7:882-92. The Impact of ARBs on HFpEF with Worsening Renal Function Quadripolar Leads: The Future of CRT-D or a Lead Too Far? Stuart J. Pocock, PhD: “There is a whole history of effective, good clinical trials researching drugs. In the States for a long time, it was felt that the device trial methodology was lagging 10 years behind. The situation is worse in Europe. To get a new cardiovascular device approved in Europe, you do not have to do randomized trials. You just need to do a short-term registry with a limited number of patients and the device will likely get approved.” Kevin Damman, MD, PhD: “We now begin to realize that not all of these incremental changes in creatinine give a worse outcome. We tend to think that when an ACE-inhibitor is started you can accept some increase in creatinine, but for HF with preserved ejection fraction (HFpEF) it’s different because we don’t have any randomized controlled trials that show any benefit from any treatment.” Rachel J. Lampert, MD: “Basically, the quadripolar lead allows you to put the lead far out into the apex, where you don’t necessarily want to pace, but you can put the lead far out where you can get stability. From there, you can pace from a more basal location using the more proximal electrodes. So I think all of the quadripolar leads are really going to be a big advantage.” Pocock S, Gersh B. J Am Coll Cardiol. Damman K, et al. J Am Coll Cardiol. 2014;64:1615-28. 2014;64:1106-13. Do Current Clinical Trials Meet Society’s Needs? 22 CardioSource WorldNews December 2014